Patents matching “antagonist”

WO 2026106499

ANTAGONISTES DU RÉCEPTEUR DE L'ORÉXINE : COMPOSÉS 2-AZABICYCLIQUES

BIAL PORTELA & CA SA [PT] · Granted May 21, 2026 · Expires May 16, 2046

WO 2026062071

ANTAGONISTES DE TNFR1 ET AGONISTES DE TNFR2 POUR LE TRAITEMENT DE LA DOULEUR AIGUË

RESANO GMBH [DE] · Granted Mar 26, 2026 · Expires Mar 21, 2046

WO 2026013287

DÉRIVÉS DE QUINAZOLINE UTILISÉS EN TANT QU'ANTAGONISTES DE GIPR

ASTRAZENECA AB [SE] · Granted Jan 15, 2026 · Expires Jan 10, 2046

WO 2025259831

FORMES CRISTALLINES D'UN ANTAGONISTE DE LPA1

BRISTOL MYERS SQUIBB CO [US] · Granted Dec 18, 2025 · Expires Dec 13, 2045

WO 2025247801

DÉTERMINATION D'UN DOSAGE D'UN ANTAGONISTE DU RÉCEPTEUR MINÉRALOCORTICOÏDE NON STÉROÏDIEN

BAYER AG [DE] · Granted Dec 4, 2025 · Expires Nov 29, 2045

US 12421517

Genetic modification of mammalian cells to confer resistance to CSF1R antagonists

The Regents of the University of California · Granted Sep 23, 2025 · Expires Sep 18, 2045

US 12421317

Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

US 12398212

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

US 12396988

Methods of using muscarinic antagonists in the treatment of depression

The Board of Regents of the University of Texas System · Granted Aug 26, 2025 · Expires Aug 21, 2045

US 12390462

Muscarinic acetylcholine M1 receptor antagonists

Contineum Therapeutics, Inc. · Granted Aug 19, 2025 · Expires Aug 14, 2045

US 12383536

CRF receptor antagonists and methods of use

Neurocrine Biosciences, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

US 12377135

GHRH antagonists for use in a method of treating sarcoidosis

United States Government as represented by the Department of Veterans Affairs · Granted Aug 5, 2025 · Expires Jul 31, 2045

US 12370181

Regimens of estrogen receptor antagonists

Olema Pharmaceuticals, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

US 2025195525

ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS

BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Jun 19, 2025 · Expires Jun 14, 2045

US 12331099

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

US 12325708

Adenosine 2 receptor antagonists

Nektar Therapeutics · Granted Jun 10, 2025 · Expires Jun 5, 2045

US 12286483

Method of treating cancer using CD137 antibodies and PD-1 antagonists

Compass Therapeutics LLC · Granted Apr 29, 2025 · Expires Apr 24, 2045

US 12280046

Melanocortin subtype-2 receptor (MC2R) antagonist for the treatment of disease

CRINETICS PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

US 12280093

Use of a VEGF receptor-based fusion protein antagonist to treat nonproliferative diabetic retinopathy

REGENERON PHARMACEUTICALS, INC. · Granted Apr 22, 2025 · Expires Apr 17, 2045

US 12281078

Quinoline cGAS antagonist compounds

The Board of Regents of the University of Texas System · Granted Apr 22, 2025 · Expires Apr 17, 2045

US 12268730

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Apr 8, 2025 · Expires Apr 3, 2045

US 12258316

Biphenyl compounds useful as muscarinic receptor antagonists

Theravance Biopharma R&D IP, LLC · Granted Mar 25, 2025 · Expires Mar 20, 2045

US 12252488

HPK1 antagonists and uses thereof

Nimbus Saturn, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

US 12247037

1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders

Neumora Therapeutics, Inc. · Granted Mar 11, 2025 · Expires Mar 6, 2045